Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

4.2K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
4.2K
Drug Biotransformation: Overview01:28

Drug Biotransformation: Overview

6.0K
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
6.0K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

379
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
379
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

131
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
131
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

203
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
203
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

69
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
69

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systematic Evidence Map for the Per- and Polyfluoroalkyl Substances (PFAS) Universe.

Environmental health perspectives·2026
Same author

A curated geospatial dataset of chemicals used in hydraulic fracturing and their functions.

Journal of environmental quality·2026
Same author

Can graph similarity metrics be helpful for analogue identification as part of a read-across approach?

Computational toxicology (Amsterdam, Netherlands)·2026
Same author

Building a compendium of expert driven read-across cases to facilitate an analysis of the contribution that different similarity contexts play in read-across performance.

Computational toxicology (Amsterdam, Netherlands)·2026
Same author

Development of the toxicity values database, ToxValDB: A curated resource for experimental and derived human health-relevant toxicity data.

Computational toxicology (Amsterdam, Netherlands)·2026
Same author

Approaching a 0% False Positive Rate for PFAS Determination Leveraging Only MS1 Data.

Environmental science & technology·2026

Related Experiment Video

Updated: Apr 6, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.8K

MetSim: Integrated Programmatic Access and Pathway Management for Xenobiotic Metabolism Simulators.

Louis Groff1, Antony Williams1, Imran Shah1

  • 1Center for Computational Toxicology and Exposure (CCTE), Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27711, United States.

Chemical Research in Toxicology
|April 10, 2024
PubMed
Summary

MetSim is a new framework for comparing xenobiotic metabolism simulators. Combining multiple tools improved metabolite prediction accuracy, aiding chemical risk assessment.

More Related Videos

A Pathway Association Study Tool for GWAS Analyses of Metabolic Pathway Information
05:01

A Pathway Association Study Tool for GWAS Analyses of Metabolic Pathway Information

Published on: July 1, 2020

3.3K
An Integrated Workflow of Identification and Quantification on FDR Control-Based Untargeted Metabolome
05:35

An Integrated Workflow of Identification and Quantification on FDR Control-Based Untargeted Metabolome

Published on: September 20, 2022

3.7K

Related Experiment Videos

Last Updated: Apr 6, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.8K
A Pathway Association Study Tool for GWAS Analyses of Metabolic Pathway Information
05:01

A Pathway Association Study Tool for GWAS Analyses of Metabolic Pathway Information

Published on: July 1, 2020

3.3K
An Integrated Workflow of Identification and Quantification on FDR Control-Based Untargeted Metabolome
05:35

An Integrated Workflow of Identification and Quantification on FDR Control-Based Untargeted Metabolome

Published on: September 20, 2022

3.7K

Area of Science:

  • Environmental Chemistry
  • Computational Toxicology
  • Bioinformatics

Background:

  • Evaluating environmental chemical risks requires understanding xenobiotic metabolism.
  • Existing metabolite simulation tools have varied formats and limited comparability.
  • Comparing the performance and coverage of these tools is a significant challenge.

Purpose of the Study:

  • To develop a standardized framework, MetSim, for harmonizing and comparing in silico metabolic simulators.
  • To create a system for evaluating the performance and coverage of different metabolic simulation tools.

Main Methods:

  • Developed a graph-based schema for harmonizing metabolism data.
  • Implemented the schema in MongoDB for storing and retrieving metabolic graphs.
  • Integrated four simulators: BioTransformer, OECD Toolbox, EPA's CTS, and TIMES.
  • Compiled a dataset of 112 drugs and 432 metabolites for prediction.
  • Evaluated simulator performance using recall and precision metrics.

Main Results:

  • Individual simulator recall ranged from 0.39 to 0.54.
  • Combining predictions from all simulators increased overall recall to 0.73.
  • MetSim facilitated efficient derivation of insights into simulator performance.

Conclusions:

  • MetSim provides a valuable platform for assessing in silico metabolic simulators.
  • Standardized comparison aids in selecting appropriate tools for chemical risk evaluation.
  • Future efforts can leverage MetSim to evaluate other datasets and improve predictive accuracy.